Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (REDEMPTION)

• Sustained Virological Response 4 (SVR4) by Hepatitis C Virus (HVC) RNA Polymerase Chain Reaction (PCR) [ Time Frame: 4-7 months ]
  Viral load 4 weeks after cessation of treatment as measured by HCV RNA PCR, where SVR is defined as HCV RNA < Lower Limit Of Quantification (LLOQ)
  
  

• Side Effects [ Time Frame: 3-6 months ]
  Collating common side effects on treatment
  
  
• Rapid Virological Response (RVR) by HCV RNA PCR [ Time Frame: 4 weeks ]
  Viral load 4 weeks after starting treatment as measured by HCV RNA PCR
  
  
• End Of Treatment (EOT) Response by HCV RNA PCR [ Time Frame: 3-6 months ]
  Viral load at end of treatment as measured by HCV RNA PCR
  
  
• Sustained Virological Response (SVR12) by HCV RNA PCR [ Time Frame: 6-12 months ]
  Viral load 12 weeks after cessation of treatment as measured by HCV RNA PCR, where SVR is defined as HCV RNA < Lower Limit Of Quantification (LLOQ)
  
  

The high prices of Hepatitis C Virus (HCV) Direct Acting Antiviral (DAA) medications in many countries have led patients to seek out less expensive generic alternatives.

The efficacy and safety of these generic medications has not been formally demonstrated in clinical practice.

The primary goal of REDEMPTION is to collate the clinical results of these generic medications.

The secondary goal is to answer efficacy questions for which there is currently insufficient trial data available - for example Sofosbuvir+Daclatasvir appears to be an inexpensive pan genotypic solution to treat HCV globally but this is supported by a total n of less than 1000, and in some common genotypes, such as HCV Genotype 2, by an n of only 52 making for a wide margin of error and a high degree of uncertainty.